Transgender People in the South American Context

Dr. Javier R. Lama

Multiple Principal Investigator, IMPACTA PERU Clinical Trials Unit Director of Research, Asociacion Civil Impacta Salud y Educacion



HIV Prevalence and Incidence among Transgender Women in South America

Location	Sampling Method	Sample Size	Prevalence, % n (Incidence)
Lima, Peru	Snowball	207	16.9 2.3/100 p-y
Multicity, Brazil	Gender clinic	284	25.0 (n=71)
Multicity, Argentina	TSW	273	34.1 (n=93)
Multicity, Peru	Convenience	709	14.4 (n=102)
Lima, Peru	Mobile testing	208	30.8 (n=64)
Multicity, Paraguay	Not specified	311	27
Fortaleza, Brazil	RDS	304	12
Lima, Peru	RDS	420	29.6

Poteat T et al. Global epidemiology of HIV infection and related syndemics affecting transgender people. J Acquir Immune Defic Syndr 2016; 72;S210-2019.

HIV Prevalence and Incidence among Transgender Women in South America

Locatinon	Sampling Method	Sample Size	Prevalence, % n (Incidence)
San Salvador, El Salvador	RDS	67	19
Bogota, Colombia	RDS	58	13.8 (n=8)
Guayaquil, Ecuador	iPrEx screen	131	16.8
Fortaleza, Brazil	RDS	208 ever tested	12
Campo Grande, Brazil	Purposive	152	24.4 (n=37)
Multicity, Argentina	Snowball, quota	452	27.4 (n=104)

Poteat T et al. Global epidemiology of HIV infection and related syndemics affecting transgender people. J Acquir Immune Defic Syndr 2016; 72;S210-2019.

Importance of assessing HIV vulnerabilities among transgender women

- Extreme health disparity
 - High HIV prevalence and incidence rates
 - Limited access to health insurance
 - 89% of transgender women in Lima, Peru
- Reduced citizenship
 - No access to healthcare, government services or vote
 - >10% of transgender women in Lima, Peru do not have their Peruvian identity document

Perez-Brumer AG et al. HIV vulnerabilities, gender affirmation, and social resilience among transgender women in Lima, Peru. A community-based approach to HIV prevention, care and treatment. IAS 2016.

Costa AB et al. HIV-related healthcare needs and Access barriers for Brazilian transgender and gender diverse people. AIDS Behav 2018.

Importance of assessing HIV vulnerabilities among transgender women

- Economic and social marginalization
 - Pervasive discrimination limiting opportunities of economic advancement irrelevant of other qualifications such as educational attainment

- Limited engagement with existing HIV prevention, treatment, and care services
 - Layered and intersecting stigmas including, sex workerbased stigma, transphobic attitudes, and HIV-related stigma

Perez-Brumer AG et al. HIV vulnerabilities, gender affirmation, and social resilience among transgender women in Lima, Peru. A community-based approach to HIV prevention, care and treatment. IAS 2016.

Costa AB et al. HIV-related healthcare needs and Access barriers for Brazilian transgender and gender diverse people. AIDS Behav 2018.

Unveiling of HIV dynamics among transgender women in Rio de Janeiro

- Transwomen bear the largest burden of HIV among any population at risk in Brazil.
 - n=345 TW (Aug 2015,- Jan 2016)
 - 29·1% had no previous HIV testing
 - HIV prevalence: 31.2%
 - 7.0% were newly diagnosed
 - Black race (OR: 22·8; p=0·003)
 - Travesti (OR: 34·1; p=0·0001)
 - Transsexual woman (OR: 41·3; p=0·0001)
 - Sex work (OR: 30·7; p=0·002)
 - Cocaine consumption (OR: 4·4; p=0·01).
 - Syphilis prevalence: 28.9%; Rectal chlamydia: 14.6%; Rectal gonorrhea: 13.5%

Grinsztejn B et al. Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil. Lancet HIV 2017, 4:e169-76.

Successful implementation of PrEP Brasil for MSM and TW: 48 week results

- Demonstration Project of oral TDF/FTC at three referral centers for HIV prevention in Rio de Janeiro and Sao Paulo
- n = 450 participants initiated PrEP (Apr 2014 July 2016)
- 83% (n=375) retained at week 48
 - 74% had protective drug concentrations consistent with at least four doses per week

Sao Paulo (82%) vs. Rio de Janeiro (63%) aOR: 1.88
Sex with HIV+ (80%) vs. no (70%) aOR: 1.78
Use of stimulants (87%) vs. no (71%) aOR: 2.23

Protective concentrations at week 4 (80%) vs. no (54%)
 aOR: 3.28

Grinsztejn B et al. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil. 48 week result of a demonstration study. Lancet HIV 2018; 5: e136–46.

Successful implementation of PrEP Brasil for MSM and TW: 48 week results




Figure 2: Sexual behaviours among study participants

- (A) Percentage of participants reporting condomless receptive anal sex and
- (B) mean number of partners in the previous 3 months.

Grinsztejn B et al. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil. 48 week result of a demonstration study. Lancet HIV 2018; 5: e136–46.

High willingness to use HIV pre-exposure prophylaxis among transgender women in Argentina

- TW face a disproportionately high prevalence of HIV infection (34%)
- Nationwide cross-sectional survey conducted among transgender women in 2013
 - n= 337 (278 VIH negative; 59 unknown HIV status)
 - Willingness to use PrEP: 89.3%

Casual sexual partners
 AOR=4.26

Discrimination by healthcare workers AOR=0.33

- High perception of HIV risk in this population
- Multilevel interventions that address gender-based stigma in healthcare settings will be critical for the success of PrEP

Zalazar V et al. High willingness to use HIV pre-exposure prophylaxis among transgender women in Argentina. Transgend Health 2016 1(1):266-73

Peru: Critical role of medical and research mistrust in acceptability of PrEP

- Medical and research mistrust emerged as key, multidimensional and interrelated barriers to PrEP acceptability including:
 - Mistrust of health care systems and providers
 - Wariness of research focused on TW
 - Suspicions of PrEP efficacy, and
 - Fear of potential adverse effects.
- Disillusionment with
 - Experimental trial designs (blinded allocation to placebo versus study drug)
 - Perceived drug effects (questions of Truvada efficacy), and
 - Study staff (mistrust of reported results, lack of information on side effects or potential interactions with hormone therapy)

Perez-Brumer A. et al. "Como conejillo de indias": critical role of medical and research mistrust in acceptability of PrEP among transgender women in Lima, Peru. IAS 2016.

Peru: Critical role of medical and research mistrust in acceptability of PrEP

- Participants voiced suspicion of research and apprehension regarding the current public health emphasis on TW as a "key population" for HIV prevention efforts.
- Participants' discussion regarding transphobia among medical providers further emphasized the perceived focus on TW as disingenuous. These narratives also questioned the scientific community''s labeling of TW as "high-risk" (especially compared to their cisgender male sexual partners).



TransPrEP: Social Network-Based PrEP Adherence for Transgender Women in Peru





THE FENWAY INSTITUTE

Social Framework

- Social marginalization, with limited support from family or neighborhood communities
- Communities are frequently connected through dense social and geographic networks
 - Social and economic support outside of traditional community systems
 - Disseminate new information and ideas
 - Define and maintain social norms of behavior
 - Provide a critical framework for the introduction and dissemination of new prevention interventions
- Networks have not previously been studied as a part of HIV prevention research

TransPrEP: A social network-based intervention to promote PrEP adherence

- Phase 1: To optimize content for an adherence intervention
- Phase 2: To conduct a six-month open evaluation of the adherence intervention
- Phase 3: To conduct a six-month pilot RCT
 - Six social network-based clusters
 - Three clusters per arm
 - Recruited from 2 seeds matched from each of 3 geographical areas
 - Randomized to
 - Network-based PrEP adherence intervention, or
 - Standardized adherence counseling
 - Primary outcome: Adherence to PrEP
 - Wisepill monitoring
 - Blood drug levels
 - Self-report

Gender-Affirmative Transgender Care to Improve the HIV Treatment Cascade

- Objective: To implement and culturally adapt The Fenway Institute model of transgender medicine, to improve the HIV treatment cascade among transgender women, via an innovative service delivery model that integrates:
 - HIV prevention and treatment services, with
 - Gender-affirming transgender medical care, supported by
 - Peer health navigation.





Continuum of HIV Care

 Due to stigma and discrimination, TW are frequently discouraged from accessing HIV care

 Absence of clinically and culturally competent medical care

 They constitute a target population for the evaluation of innovative interventions that address the continuum of HIV care





- Absence of standard protocols to implement
 - Cross-sex hormone therapy, or
 - Gender enhancement/transition procedures
- It is usually informal and peer-delivered
 - Use of female contraceptives
 - No appropriate dosing, blood monitoring, or medical and psychological follow-up
 - Enhancement procedures conducted at no medical settings
 - No services for sex re-assignment surgery

Implementation



- Phase 1: Formative
 - Community engagement and education
 - Mixed-methods formative research
 - Training and interventional protocol writing
- Phase 2: Intervention
- Phase 3: Dissemination of intervention and study results
 - "Best Practices" document
 - Search political involvement for scaling-up

Mixed-Methods Formative Research: Key Findings





ORIGINAL PAPER

Perceived Barriers and Facilitators to Integrating HIV Prevention and Treatment with Cross-Sex Hormone Therapy for Transgender Women in Lima, Peru

Sari L. Reisner^{1,2,3} · Amaya G. Perez-Brumer⁴ · Sarah A. McLean¹ · Javier R. Lama^{5,6} · Alfonso Silva-Santisteban⁷ · Leyla Huerta⁸ · Jorge Sanchez^{6,7} · Jesse L. Clark⁹ · Matthew J. Mimiaga^{1,3,10} · Kenneth H. Mayer^{1,11,12}

Perez-Brumer AG et al. Journal of the International AIDS Society 2017, 20:21462 http://www.jiasociety.org/index.php/jias/article/view/21462 | http://dx.doi.org/10.7448/IAS.20.1.21462



Research article

Leveraging social capital: multilevel stigma, associated HIV vulnerabilities, and social resilience strategies among transgender women in Lima, Peru

Amaya G. Perez-Brumer 615, Sari L. Reisner A., Sarah A. McLean, Alfonso Silva-Santisteban, Leyla Huerta, Kenneth H. Mayer, Jorge Sanchez 78,9, Jesse L. Clark, Matthew J. Mimiaga 2,11 and Javier R. Lama 7,8

Integrated care model: High perceived acceptability

Barriers

 Stigma, lack of provider training or Peruvian guidelines regarding optimal transgender care, and service delivery obstacles

Facilitators


 Engagement and involvement of transgender women in healthcare service provision, delivery, and linkages

Leveraging social capital

 Peer trust and cooperative relationships facilitates routine access to needed healthcare services

Intervention: Baseline Data





11 (4.4%)
5
5
1
20 (8.0%)
11
6
3

Age, years

Median [IQR]	26 [23 - 32]
Range	18 - 58

Cross-sex hormone therapy ever

	150	68.8%
Injection	87	58.0%
Pill	42	28.0%
Patch	2	1.3%
Multiple methods	19	12.7%

HIV test ever

	169	77.5%
Time since most recent test		
During the past month	35	20.7%
During the past 3 months	41	24.3%
During the past 6 months	31	18.3%
During the past year	9	5.3%
More than a year ago	47	27.8%
No response	6	3.6%

Result most recent test

Negative	151	89.3%
Positive	11	6.5%
Never received result	1	0.6%
No response	6	3.6%

Baseline HIV & Syphilis Diagnosis

HIV infection	44	20.0%
Reactive syphilis serology	47	21.4%
Early syphilis	10	4.5%